Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis

[1]  L. Køber,et al.  A meta‐analysis of the effect of angiotensin‐converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction , 2004, European journal of heart failure.

[2]  L. Køber,et al.  The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. , 2003, European heart journal.

[3]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[4]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[5]  J. Hampton,et al.  Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group. , 1998, European heart journal.

[6]  K. Caidahl,et al.  Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants , 1996, Clinical cardiology.

[7]  K. Swedberg,et al.  What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. , 1996, European heart journal.

[8]  B. Trimarco,et al.  Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment Comparison with long-term clinical effect , 1996, European Journal of Clinical Pharmacology.

[9]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[10]  L. Erhardt,et al.  Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. , 1995, European heart journal.

[11]  E. J. Brown,et al.  Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. , 1995, The American journal of cardiology.

[12]  K. Watanabe,et al.  Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. , 1995, Cardiology.

[13]  D. Dössegger.  Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group. , 1995, Cardiology.

[14]  K. Swedberg,et al.  Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group. , 1994, European heart journal.

[15]  L. T. Sheffield,et al.  Quality-of-life Among 5,025 Patients With Left-ventricular Dysfunction Randomized Between Placebo and Enalapril - the Studies of Left-ventricular Dysfunction , 1994 .

[16]  L. T. Sheffield,et al.  Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. , 1994, Journal of the American College of Cardiology.

[17]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[18]  J. Bounhoure,et al.  Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. , 1993, American heart journal.

[19]  J. Cleland,et al.  Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. , 1993, European heart journal.

[20]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[21]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[22]  A. Gradman,et al.  Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group. , 1992, The American journal of cardiology.

[23]  F. Kleber,et al.  Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. , 1992, British heart journal.

[24]  G. Keren,et al.  Left ventricular filling dynamics by Doppler echocardiography in dilated cardiomyopathy: one-year follow-up in patients treated with captopril compared to placebo. , 1992, Cardiology.

[25]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[26]  G. Riegger.  Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. , 1991, European heart journal.

[27]  H. Drexler,et al.  Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. , 1989, Circulation.

[28]  B. Magnani.  Converting enzyme inhibition and heart failure. , 1988, The American journal of medicine.

[29]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[30]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[31]  M. Joy,et al.  Long term use of enalapril in the treatment of patients with congestive heart failure. , 1987, International journal of cardiology.

[32]  M. Dunn,et al.  Hemodynamic and metabolic effects of enalapril in patients with heart failure , 1985, Clinical cardiology.

[33]  C. Johnston,et al.  Controlled trial of enalapril in congestive cardiac failure. , 1985, British heart journal.

[34]  V. Kalff,et al.  Enalapril for severe congestive heart failure , 1984, The Medical journal of Australia.

[35]  D. Sharpe,et al.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. , 1984, Circulation.

[36]  A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. , 1983, Journal of the American College of Cardiology.